Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease

Sponsor
Chinese University of Hong Kong
Study ID
NCT06727409
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Patients With Type 2 Diabetes

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Finerenone — DRUG
    Finerenone 10mg or 20 mg as tolerated on top of maximal tolerated RASi and stable SGLT2i therapy

Study Details

To evaluate triple therapy with nsMRA, RASi and SGLT2i on albuminuria in individuals with T2D and CKD

Key Dates

Start date
Dec 12, 2024
Status verified
Dec 2024
Primary completion
Jul 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
82 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Finerenone on top of maximal tolerated RASi and stable SGLT2i therapy
    pre and post Finerenone treatment evaluation

Primary Outcome Measure

Change in urine albumin creatinine ratio (uACR) [ Time Frame: 26 weeks ]

Central Contacts